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Abstract 
 
Background: Kawasaki disease is one of the leading causes of acquired heart disease in 
children. It is an acute self-limited vasculitis that predominantly affects infants and children 
younger than 5 years of age. These patients present with nonspecific symptoms, such as fever 
and lymphadenopathy, making the diagnosis challenging. This disease can have serious and 
potentially fatal outcomes, and prompt recognition of this disease is vital to the patient’s 
outcome. We present a complete review of the disease, including the epidemiology, 
pathophysiology, diagnosis and management of acute Kawasaki disease, the natural history of 
this disease, and follow up of these patients as they transition into the adult cardiology practice. 
 
Methods: Our systematic review information was collected from articles retrieved from PubMed 
library. Keywords that were used included; Kawasaki disease, coronary artery disease, coronary 
artery aneurysm, pediatric coronary artery disease, epidemiology of Kawasaki disease and 
treatment of Kawasaki disease. We included only relevant to the topic articles. No exclusion 
criteria were applied. 
   
Conclusions: Kawasaki disease incidence tends to be increasing over the last decade in the 
United States. Seasonality of the disease has been described in Japan. It is a mysterious disease 
with unknown etiology, however, multiple hypotheses have been proposed and tested to explain 
the pathophysiology. As this disease has an associated high morbidity and mortality, prompt 
recognition and management are important to the patient’s overall prognosis and survival.  
 
Keywords 
 
Kawasaki disease, coronary artery aneurysms, coronary artery disease 
 
Introduction 
 
Kawasaki disease (KD), previously known as mucocutaneous lymph node syndrome, is an acute 
self-limited vasculitis that predominantly affects infants and children younger than 5 years of 
age. The disease was first described in Japan by Tomisaku Kawasaki in 1967 and is known to 
occur in both Americas, Europe, and Asia; Japan has recorded the highest incidence and 
prevalence of the disease across the globe.1,2,3 Patients present with nonspecific symptoms, such 
as fever and lymphadenopathy, making the diagnosis challenging.3 Kawasaki disease can have 
serious and potentially fatal outcomes, and prompt recognition of this disease is vital to the 
patient’s outcome.  
 
Methods 
 
Our systematic review information was collected from articles retrieved from PubMed library. 
Keywords that were used included: Kawasaki disease, coronary artery disease, coronary artery 
aneurysm, pediatric coronary artery disease, epidemiology of Kawasaki disease and treatment of 
Kawasaki disease. We included only relevant to the topic articles. No exclusion criteria were 
applied. Twenty-eight articles were selected as a source of information.  
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Epidemiology 
 
The prevalence of KD is reportedly the highest in Japan and in those with Japanese descent.4 In 
2012, data from Japan revealed that the annual incidence was 264.8 cases per 100,000 children 
aged 0-4 years per year.5 Reported data from US has been based on hospital discharge data; it 
appears that in 2000, 4248 hospitalizations in patients with KD were noted and there has not 
been a significant increase in the last decade.6 In regard to gender, data from the United States 
reports an incidence of boys: girls at 1.5:1, suggesting that this disease is more common in 
males.5 Interestingly, there are also seems to be an association with seasonality. Japan and Korea 
have both reported peaks in January and July, with a nadir in October.7-9 In contrast, KD occurs 
more commonly during the winter and early spring months in the United States.10 The fatality 
rate from KD in Japan has been reported as high as 0.08% and all deaths from KD are a result of 
cardiac sequelae.3 
 
Pathophysiology 
 
The etiology of this mysterious disease is unknown and there have been multiple attempts to 
explain this disease by an infection and toxins, however, trials have failed to show an 
association. As young infants rarely have been reported to have this disease, there is a theory that 
there is some protection from maternal antibodies.3  
 
On a microscopic level, in acute KD it has been shown that both the innate and adaptive immune 
systems are involved. Neutrophils are among the first responders to invade the arterial wall and 
are followed by CD8+ T cells, dendritic cells, and monocyte/macrophages.11,12 Increased 
transcript abundance for IL-1 related genes by microarray and quantitative real-time polymerase 
chain reaction, and increased levels of IL-1 pathway proteins in plasma support the activation of 
the interleukin (IL)-1 pathway in Kawasaki disease.13  
 
Also in KD, as in giant cell arteritis,14 two dominant cytokine clusters are recognized: the IL-6/T 
helper (Th)-17 axis and the IL-12/interferon gamma axis. IL-6, in combination with transforming 
growth factor beta (TGFb), polarizes naïve T cells toward a Th-17 phenotype, resulting in these 
cells invading the vessel wall and elaborating a proinflammatory cytokine profile.15,16 
 
Diagnosis 
 
With the unknown and unidentified etiology of Kawasaki disease, the diagnosis remains based 
on careful clinical evaluation of patients with suspected KD.17 The nonspecific symptoms and 
signs of KD are shared with multiple other diseases and conditions, thus, one should be very 
thorough and systematic to rule out a broad differential diagnosis (Table 1).18 The 2004 
American Heart Association (AHA) guidelines and the fifth edition of the Japan Diagnostic 
Guidelines (JDG) both list six principal clinical features for KD diagnosis.3,17 While the AHA 
guidelines considers having a prolonged fever (more than five days) an essential element for the 
diagnosis of KD, the JDG gives the prolonged fever equal weight to other clinical features.3,17 
Along with prolonged fever, patients who meet complete (typical) AHA KD diagnosis criteria 
should also have four of the following principal clinical features: 1) bilateral conjunctival 
injection, 2) changes of the mucous membranes (chapped lips, strawberry tongue, or injected 
pharynx, 3) polymorphous skin rash, 4) changes in the extremities (swelling of hands and feet, 
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erythema, or periungal desquamation), 5) cervical lymphadenopathy (usually unilateral, and it is 
the least common finding).3  
 
Table 1: Differential Diagnosis of Kawasaki Disease. Similar disease and conditions.  
Viral disease Measles, Epstein-Barr Virus (Mononucleosis), Influenza, 
Adenovirus, and Enterovirus  
Bacterial 
Infections  
Scarlet Fever, Staphylococcal Scalded Skin Syndrome, 
Mycoplasma infections, Rocky Mountain Spotted Fever, 
Leptospirosis, and Bacterial Cervical Lymphadenitis (abscesses)  
Immunological, 
or autoimmune 
Drug reactions, Vaccine reactions, Juvenile rheumatoid arthritis, 
Mercury hypersensitivity reaction, and insect bites  
 
Not all patients with suspected KD develop five principal clinical features. There is a portion of 
KD patients that develop four or less of the principal symptoms and signs.4 These subsets of 
patients have been described under the term of atypical (or incomplete) KD.3  Atypical KD has 
been described mostly in ages less than 6 months and older than 10 years.19 These patients have a 
higher incidence rate of coronary artery lesions, the major complication of KD.19 As atypical KD 
cases do not fulfill the criteria for complete KD diagnosis, the evaluating clinician should look 
for other supportive clinical and laboratory supplementary findings of KD. The supplementary 
findings are detailed by systems in Table 2.3,17 With the suspicion of KD (prolonged fever) and 
incomplete fulfillment of clinical criteria (presence of 2 or 3 other principal clinical features), 
patients should undergo continuous clinical reassessment to look for further development of the 
missing principal features. Simultaneously, laboratory evaluation should take place to look for 
supplementary laboratory evidence (Table 2). If the patient meets incomplete criteria for KD, 
echocardiographic evaluation is warranted.3 
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Table 2: Other significant symptoms and findings for patients with suspected KD. 
Findings are listed by systems.  
Cardiovascular Findings consistent with heart failure, myocardial infarction, or 
arrhythmias (heart murmur, gallop, prolonged PR, QT, ST changes, 
EKG findings consistent with arrhythmias, radiologic or 
echocardiographic findings of congestive heart failure);  
aneurysms of coronary arteries and non-coronary medium sized 
arteries  
Gastrointestinal  Diarrhea, vomiting, abdominal pain, hydrops of gall bladder, ileus, 
hypoalbuminemia, transaminitis, and jaundice 
Hematopoietic Leukocytosis with leftward shift, thrombocytosis, and anemia   
Renal Proteinuria, and sterile pyuria  
Skin Reaction to Bacille Clamette-Gluèrin inoculation with redness and 
induration; pustules  
Neurological  Irritability, pleocytosis of cerebrospinal fluid, seizures, peripheral 
facial palsy, and paralysis of extremities  
Musculoskeletal 
and inflammatory  
Arthralgia, joint swelling; elevated erythrocyte sedimentation rate 
(ESR), elevated C-reactive protein(CRP)  
Respiratory  Rhinorrhea, cough  
Laboratory 
findings  
Leukocytosis with leftward shift  
Elevated ESR 
Elevated CRP 
Anemia 
Abnormal plasma lipids 
Hypoalbuminemia 
Hyponatremia 
Thrombocytosis after week 1 
Sterile pyuria 
Elevated serum transaminases 
Elevated serum gamma glutamyl transpeptidase 
Pleocytosis of cerebrospinal fluid 
Leukocytosis in synovial fluid 
 
Management of Acute KD 
 
The main rationale behind administering the acute treatment for KD cases is to prevent coronary 
artery lesions and decrease its burdens.3 Optimally, and to have the best response, acute 
treatment should be instituted in the first ten days of illness.3 The most effective regimen that has 
been described consists of high dosage (2g/kg) of intravenous immunoglobulin (IVIG) infusion.3 
Along with IVIG infusion, a high dosage of aspirin (80 to 100 mg/kg/day) should be 
administered to achieve anti-inflammatory and antiplatelet effect.3 IVIG should be infused 
slowly over eight to twelve hours. Infusion may be repeated if fever persists 36-48 hours after 
the first infusion.3 High dosage aspirin is recommended during the period that the patient is 
symptomatic (usually the first 48 hours).3,17 Antiplatelet aspirin dosage (5 mg/kg/day) is 
indicated until long-term follow up is completed.3,17 Other regimens of acute treatment for KD, 
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most commonly conjunctional use of steroids, have been described in cases of resistant KD 
cases.20,21  
 
The ultimate management of patients with KD also requires an initial echocardiographic 
evaluation of their coronary arteries along with complete echocardiographic study.3 This baseline 
echocardiographic coronary evaluation helps stratify the coronary risk for patients with KD, and 
it determines the antithrombotic treatment and follow-up schedule they should follow.7 Patients 
with no coronary artery lesions (Z Scores < 2) should be on low dosage aspirin (antiplatelet 
therapy) for four to six weeks, with repeated echocardiographic evaluations in two weeks and six 
to eight weeks after the onset of illness.3 Patients with higher coronary risks with dilated 
coronary artery diameters (Z scores > 2.5) will undergo a lifelong follow up for surveillance of 
worsening aneurysms and tailoring of antithrombotic treatment based on their coronary risk.22,23  
 
Natural History and Cardiac Findings 
 
Cardiac findings that have been reported in the literature include coronary aneurysms, 
myocarditis, mitral regurgitation from papillary muscle dysfunction, myocardial infarction, or 
valvulitis. These abnormalities can be identified by echocardiography, magnetic resonance 
imaging (MRI)/magnetic resonance angiogram (MRA), and/or cardiac angiography.3  
 
With a specific focus on coronary artery aneurysms, it is noted that the morphology of coronary 
arteries changes dynamically with time in KD. Aneurysms may increase in size in the first two 
months of illness; resolution generally occurs in one to two years in 50-67% of patients after 
disease onset.24,25 The resolution of the aneurysm depends on multiple factors such as the age of 
onset of disease, initial morphology, location and size of aneurysm. For example, the smaller the 
size of aneurysm, the greater the likelihood of resolution. The worst consequences appear to 
occur in giant aneurysms (maximum diameter >8mm).26 In giant aneurysms, there can be 
stenotic lesions on either side of the aneurysmal sac due to marked proliferation of the 
myointima, which can result in high morbidity and mortality.25 Interestingly, the coronary artery 
aneurysms that undergo resolution have an abnormal histopathology; specifically, they have a 
decreased vascular response to isosorbide dinitrate, indicating endothelial dysfunction.27  
 
Therapeutic regimens to prevent thrombosis of coronary arteries in these patients include 
antiplatelet therapy with aspirin, +/- clopidogrel or dipyridamole, anticoagulation with warfarin, 
or a combination of antiplatelet and anticoagulant therapy based on risk stratification (see 
below). It should be noted, however, that these patients who develop acute thrombosis should not 
be treated as if this was due to plaque rupture; therefore, thrombolytics have been suggested and 
therapy with aspirin, heparin, and glycoprotein IIb/IIIa inhibitors should be utilized. Catheter 
intervention with balloon angioplasty, rotational ablation, and stent placement can be utilized; 
however, if this is not successful and the patient has severe left ventricular dysfunction or vessels 
with multiple, ostial, or long-segment lesions, then coronary artery bypass surgery is 
recommended.3  
 
Patients with KD tend to have higher adverse cardiac risk profiles, with higher blood pressures 
and derangements in lipid profiles.28 The population of children with KD reaching adulthood is 
growing. Hence, risk stratification and follow up of these patients are vital for long-term 
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management. Listed below is a consensus by experts in regard to classifying these patients and 
management.3   
 
• Risk Level I: echocardiography does not show any coronary artery changes at any stage 
of the illness 
o Pharmacological therapy: none beyond 1st 6-8 weeks 
o Physical activity: no restrictions beyond 1st 6-8 weeks 
o Follow up and Diagnostic Testing: cardiovascular risk assessment, counseling at 
5-year intervals 
o Invasive testing: not recommended 
• Risk Level II: echocardiography shows transient coronary artery ectasia or dilatation that 
is known to disappear within the first 6-8 weeks 
o Pharmacological therapy: none beyond 1st 6-8 weeks 
o Physical activity: no restrictions beyond 1st 6-8 weeks 
o Follow up and Diagnostic Testing: cardiovascular risk assessment, counseling at 
3-5 year intervals 
o Invasive testing: not recommended 
• Risk Level III: echocardiography or angiography shows isolated (solitary) small to 
medium (3-6 mm or Z score between 3 and 7) coronary artery aneurysm in 1 coronary 
arteries 
o Pharmacological therapy: low dose aspirin (3-5 mg/kg aspirin/d), at least until 
aneurysm regression is documented 
o Physical activity: 
▪ <11 years of age: no restrictions beyond 1st 6-8 weeks 
▪ 11-20 years of age: physical activity guided by stress test, evaluation of 
myocardial perfusion scan; contact or high-impact sports discouraged for 
patients taking antiplatelet agents 
o Follow up and Diagnostic Testing: annual cardiology follow up with 
echocardiogram and EKG, combined with cardiovascular risk assessment 
counseling; biennial stress test/evaluation of myocardial perfusion scan 
o Invasive testing: angiography if noninvasive test suggests ischemia 
• Risk Level IV: 1 large coronary artery aneurysm (6 mm) and coronary artery that 
contains multiple (segmented) or complex aneurysms without obstruction 
o Pharmacological therapy: long-term antiplatelet therapy + warfarin with INR goal 
2-2.5 OR low molecular weight heparin (target antiXa level of 0.5-1.0) should be 
combined in giant aneurysms 
o Physical activity: avoid contact or high-impact sports due to higher risk of 
bleeding; other restrictions are guided by stress test/evaluation of myocardial 
perfusion scan outcome 
o Follow up and Diagnostic Testing: biannual follow up with echocardiogram and 
EKG; annual stress test/evaluation of myocardial perfusion scan 
o Invasive testing: first angiography at 6-12 months or sooner if clinically indicated; 
repeated if noninvasive testing, clinical/laboratory findings suggest ischemia  
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• Risk Level V: angiography confirms the presence of coronary artery obstruction 
o Pharmacological therapy: long-term low-dose aspirin; if presence of giant 
aneurysm, add warfarin or low molecular weight heparin; consider beta blockers 
to reduce myocardial oxygen consumption 
o Physical activity: avoid contact or high-impact sports due to higher risk of 
bleeding; other restrictions are guided by stress test/evaluation of myocardial 
perfusion scan outcome 
o Follow Up and Diagnostic Testing: biannual follow up with echocardiogram and 
EKG; annual stress test/evaluation of myocardial perfusion scan 
o Invasive testing: angiography recommended to address therapeutic options 
 
Case 
 
We present a case of a 32 year old male with a history of Kawasaki disease with known coronary 
artery aneurysms, hypertension and hyperlipidemia, taking rivaroxaban, managed at an outside 
facility who was referred after a positive exercise stress test ordered for exertional chest pain and 
dyspnea. He was found to have marked ST segment depressions, mainly in the inferior leads, 
when walking on the treadmill. Subsequent left heart catheterization revealed large aneurysms in 
the left anterior descending and right coronary artery with critical stenosis (Figures A & B). The 
patient was referred for cardiac bypass surgery for further management.  
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Figure A: Mid RCA with thrombosed aneurysm 
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Figure B: Aneurysm of the proximal left anterior descending artery 
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 Summary 
 
KD is one of the leading causes of acquired cardiac disease in children, noted to be higher in 
incidence in Japan and the United States. As with our patient, coronary aneurysms have been 
known to be a common sequela of this disease. Therefore, prompt recognition and treatment 
during the acute phase of KD is important. For those patients with residual coronary disease, 
prevention and management of myocardial ischemia and dysfunction are paramount. 
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